Past, present and future of pharmacotherapy for obesity.

David Benaiges, Juan Pedro-Botet, Juana A Flores-Le Roux, Elisenda Climent, Albert Goday

Journal: Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis 2018;29(6):256-264

PMID: 28935287

Full Text on Elsevier Science View on PubMed

Abstract

Conventional treatment for obesity with diet, exercise and bariatric surgery has limitations; thus, it is necessary to have pharmacological tools. In the past, different drugs were marketed that were withdrawn due to safety problems. There are currently 3 drugs approved by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) for obesity therapy (orlistat, combination of bupropion and delayed-release naltrexone and liraglutide) and two more only authorized by FDA (lorcaserin and the combination of phentermine and extended release topiramate). It is recommended to use as a second therapeutic line and its choice should be individualized taking into account multiple aspects such as expected weight loss, route of administration, safety profile and cost. Currently there are several drugs under development that act on different therapeutic targets.

Address: Servicio de Endocrinología y Nutrición, Hospital del Mar de Barcelona, Barcelona, España; Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, España; Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, España. Electronic address: [email protected].; Servicio de Endocrinología y Nutrición, Hospital del Mar de Barcelona, Barcelona, España; Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, España; Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, España.; Servicio de Endocrinología y Nutrición, Hospital del Mar de Barcelona, Barcelona, España.

DOI: 10.1016/j.arteri.2017.06.002